688578 艾力斯
已收盘 09-30 15:00:00
资讯
新帖
简况
9月30日艾力斯涨12.61%,兴全社会责任混合基金重仓该股
证券之星 · 09-30 17:46
9月30日艾力斯涨12.61%,兴全社会责任混合基金重仓该股
艾力斯创1个月新高 伏美替尼逐步确认BIC地位
智选洞察 · 09-30 09:30
艾力斯创1个月新高 伏美替尼逐步确认BIC地位
中泰证券给予艾力斯买入评级
每日经济新闻 · 09-29
中泰证券给予艾力斯买入评级
9月27日艾力斯涨10.81%,兴全社会责任混合基金重仓该股
证券之星 · 09-27
9月27日艾力斯涨10.81%,兴全社会责任混合基金重仓该股
港股异动 | 加科思-B(01167)涨超6% 收到艾力斯1.72亿元合作付款 Pan-KRAS抑制剂国内获批临床
智通财经 · 09-27
港股异动 | 加科思-B(01167)涨超6% 收到艾力斯1.72亿元合作付款 Pan-KRAS抑制剂国内获批临床
艾力斯大幅上涨 获主力净流入986万元
智选洞察 · 09-27
艾力斯大幅上涨 获主力净流入986万元
加科思(01167.HK):收到与艾力斯独家对外许可协议首付款等1.73亿人币
阿斯达克财经 · 09-27
加科思(01167.HK):收到与艾力斯独家对外许可协议首付款等1.73亿人币
加科思-B:收到与艾力斯关于就GLECIRASIB及JAB-3312的独家对外许可协议的约1.73亿元款项
智通财经网 · 09-27
加科思-B:收到与艾力斯关于就GLECIRASIB及JAB-3312的独家对外许可协议的约1.73亿元款项
和誉医药与艾力斯合作研发的口服小分子抑制剂获批临床
新京报 · 09-25
和誉医药与艾力斯合作研发的口服小分子抑制剂获批临床
艾力斯(688578)9月23日主力资金净卖出1508.86万元
证券之星 · 09-24
艾力斯(688578)9月23日主力资金净卖出1508.86万元
艾力斯(688578.SH):AST2303片获药物临床试验批准
智通财经网 · 09-23
艾力斯(688578.SH):AST2303片获药物临床试验批准
艾力斯最新公告:AST2303片获得药物临床试验批准通知书
证券之星 · 09-23
艾力斯最新公告:AST2303片获得药物临床试验批准通知书
艾力斯09月19日主力资金流出2208万元 连续3日减仓
市场透视 · 09-19
艾力斯09月19日主力资金流出2208万元 连续3日减仓
艾力斯(688578)9月13日主力资金净卖出3154.75万元
证券之星 · 09-14
艾力斯(688578)9月13日主力资金净卖出3154.75万元
艾力斯(688578)9月11日主力资金净卖出2592.46万元
证券之星 · 09-12
艾力斯(688578)9月11日主力资金净卖出2592.46万元
艾力斯09月10日遭主力抛售2021万元 环比增加236.83%
市场透视 · 09-10
艾力斯09月10日遭主力抛售2021万元 环比增加236.83%
艾力斯(688578)9月6日主力资金净卖出3716.24万元
证券之星 · 09-07
艾力斯(688578)9月6日主力资金净卖出3716.24万元
艾力斯: 您的意见已收悉,
证券之星 · 09-06
艾力斯: 您的意见已收悉,
XD艾力斯09月05日主力资金流出953万元 连续3日减仓
市场透视 · 09-05
XD艾力斯09月05日主力资金流出953万元 连续3日减仓
艾力斯09月04日遭主力抛售1010万元 环比增加186.93%
市场透视 · 09-04
艾力斯09月04日遭主力抛售1010万元 环比增加186.93%
公司概况
公司名称:
上海艾力斯医药科技股份有限公司
所属行业:
医药制造业
上市日期:
2020-12-02
主营业务:
上海艾力斯医药科技股份有限公司是一家专注于肿瘤治疗领域的创新药企业,主要产品包括艾氟替尼(第三代EGFR-TKI)、阿利沙坦酯等。目前,已在非小细胞肺癌小分子靶向药领域构建了丰富的研发管线。公司自主研发成功并对外转让的已上市产品为阿利沙坦酯片,关于阿利沙坦酯《抗高血压化学1.1类创新药物——艾力沙坦的III期临床研究》课题获得国家“重大新药创制”科技重大专项,其临床研究入选国家高技术研究发展计划(863计划)。
发行价格:
22.73
{"stockData":{"symbol":"688578","market":"SH","secType":"STK","nameCN":"艾力斯","latestPrice":55.18,"timestamp":1727679600000,"preClose":49,"halted":0,"volume":14045778,"delay":0,"floatShares":450000000,"shares":450000000,"eps":2.4265,"marketStatus":"已收盘","marketStatusCode":5,"change":6.18,"latestTime":"09-30 15:00:00","open":53.27,"high":56.65,"low":51.5,"amount":761000000,"amplitude":0.1051,"askPrice":55.18,"askSize":242,"bidPrice":55.17,"bidSize":39,"shortable":0,"etf":0,"ttmEps":2.4265,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1728351000000},"adr":0,"adjPreClose":49,"symbolType":"stock_kcb","openAndCloseTimeList":[[1727659800000,1727667000000],[1727672400000,1727679600000]],"highLimit":53.9,"lowLimit":44.1,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":450000000,"pbRate":5.5,"roa":"--","roe":"15.23%","epsLYR":1.43,"committee":-0.613636,"marketValue":24831000000,"floatMarketCap":24831000000,"peRate":22.740572,"changeRate":0.1261,"turnoverRate":0.0312,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-10-08。","afterMarket":{"amount":0,"volume":0,"close":55.18,"buyVolume":3000,"sellVolume":0,"time":1727681637153,"indexStatus":"已收盘 09-30 15:30:00","preClose":49}},"requestUrl":"/m/hq/s/688578/wiki","defaultTab":"wiki","newsList":[{"id":"2471320874","title":"9月30日艾力斯涨12.61%,兴全社会责任混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2471320874","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471320874?lang=zh_cn&edition=full","pubTime":"2024-09-30 17:46","pubTimestamp":1727689595,"startTime":"0","endTime":"0","summary":"证券之星消息,9月30日艾力斯涨12.61%,收盘报55.18元,换手率3.12%,成交量14.05万手,成交额7.61亿元。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共56家,其中持有数量最多的公募基金为兴全社会责任混合。何以广在任的基金产品包括:兴证全球可持续投资三年定开混合,管理时间为2023年12月4日至今,期间收益率为1.44%;兴全社会责任混合的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024093000031132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239","161912"],"gpt_icon":0},{"id":"2471459188","title":"艾力斯创1个月新高 伏美替尼逐步确认BIC地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2471459188","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471459188?lang=zh_cn&edition=full","pubTime":"2024-09-30 09:30","pubTimestamp":1727659802,"startTime":"0","endTime":"0","summary":"消息解读艾力斯近期发布了伏美替尼逐步确认BIC地位的消息。中泰证券发布研报称,给予艾力斯买入评级。评级理由主要包括:1)伏美替尼逐步确认BIC地位,国内销售峰值有望超55亿元;2)海外权益已售出,未来将持续获得里程碑和销售分成;3)Lisencein补充管线,新建大分子早研平台。主营业务及业绩艾力斯公司主营业务为创新药物的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930115443a1dd8b02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930115443a1dd8b02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688578","BK0239"],"gpt_icon":0},{"id":"2471005991","title":"中泰证券给予艾力斯买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2471005991","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471005991?lang=zh_cn&edition=full","pubTime":"2024-09-29 08:47","pubTimestamp":1727570839,"startTime":"0","endTime":"0","summary":"中泰证券09月29日发布研报称,给予艾力斯(688578.SH,最新价:49元)买入评级。评级理由主要包括:1)伏美替尼逐步确认BIC地位,国内销售峰值有望超55亿元;2)海外权益已售出,未来将持续获得里程碑和销售分成;3)Lisencein补充管线,新建大分子早研平台。风险提示:商业化产品收入不及预期风险;临床开发进度不及预期风险;同类竞争对手和新技术疗法竞争风险;研究报告使用的公开资料可能存在信息滞后或更新不及时的风险。文章来源:每日经济新闻原标题:中泰证券给予艾力斯买入评级","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409290859129f1dbda8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409290859129f1dbda8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600918","688578"],"gpt_icon":0},{"id":"2470779501","title":"9月27日艾力斯涨10.81%,兴全社会责任混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2470779501","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470779501?lang=zh_cn&edition=full","pubTime":"2024-09-27 16:45","pubTimestamp":1727426730,"startTime":"0","endTime":"0","summary":"证券之星消息,9月27日艾力斯涨10.81%,收盘报49.0元,换手率1.06%,成交量4.77万手,成交额2.2亿元。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共56家,其中持有数量最多的公募基金为兴全社会责任混合。何以广在任的基金产品包括:兴证全球可持续投资三年定开混合,管理时间为2023年12月4日至今,期间收益率为-1.57%;兴全社会责任混合的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092700025110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578","161912"],"gpt_icon":0},{"id":"2470264397","title":"港股异动 | 加科思-B(01167)涨超6% 收到艾力斯1.72亿元合作付款 Pan-KRAS抑制剂国内获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2470264397","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470264397?lang=zh_cn&edition=full","pubTime":"2024-09-27 14:13","pubTimestamp":1727417625,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,加科思-B涨超6%,截至发稿,涨6.82%,报1.88港元,成交额979.72万港元。消息面上,加科思宣布收到上海艾力斯医药科技股份有限公司的1.72亿元合作付款,其中包括1.5亿元首付款,以及2279万元研发费用补偿及其他付款。这笔付款基于加科思与艾力斯于2024年8月30日签署的合作协议,加科思将KRASG12C抑制剂戈来雷塞和SHP2抑制剂JAB-3312的中国权益授权授给艾力斯。另外,由该公司自主研发的Pan-KRAS抑制剂JAB-23E73新药临床试验申请在中国获批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1188018.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK0239","01167","688578","BK1161"],"gpt_icon":0},{"id":"2470748833","title":"艾力斯大幅上涨 获主力净流入986万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2470748833","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470748833?lang=zh_cn&edition=full","pubTime":"2024-09-27 09:56","pubTimestamp":1727402197,"startTime":"0","endTime":"0","summary":"09月27日,艾力斯股价大幅上涨,截至09点56分,艾力斯上涨5.00%,报46.43元/股,成交1.24亿元,换手率0.61%,振幅4.09%。资金动向截止发稿,艾力斯获得主力净流入986万元,其中超大单流出254万元,大单流入1241万元。融资融券方面,艾力斯09月25日获得融资净买入296万元,当日该股融资余额为8.00亿元,当较前一日增加0.37%,实现2连增;该股融券余额为239万元,融券余量为5.15万股,比上日减少23.00%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240927100150ab665214&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240927100150ab665214&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688578"],"gpt_icon":0},{"id":"2470715702","title":"加科思(01167.HK):收到与艾力斯独家对外许可协议首付款等1.73亿人币","url":"https://stock-news.laohu8.com/highlight/detail?id=2470715702","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470715702?lang=zh_cn&edition=full","pubTime":"2024-09-27 08:44","pubTimestamp":1727397840,"startTime":"0","endTime":"0","summary":"加科思(01167.HK) 公布,其间接非全资附属加科思新药研发就于8月30日艾力斯就KRAS G12C抑制剂Glecirasib (JAB-21822)及SHP2变构抑制剂JAB-3312订立的对外许可协议,已收到1.73亿元人民币(下同)的款项,包括首付款1.5亿元及部分研发开支补偿及其他款项。集团认为,该首付款及部分研发开支补偿及其他款项的到账,进一步充盈其现金储备,也将为后续管线研发的推进提供助力。(jl/k)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210503161347712_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210503161347712_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1384349/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","688578","01167","BK0239","BK1574"],"gpt_icon":0},{"id":"2470066799","title":"加科思-B:收到与艾力斯关于就GLECIRASIB及JAB-3312的独家对外许可协议的约1.73亿元款项","url":"https://stock-news.laohu8.com/highlight/detail?id=2470066799","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470066799?lang=zh_cn&edition=full","pubTime":"2024-09-27 06:25","pubTimestamp":1727389507,"startTime":"0","endTime":"0","summary":"智通财经APP讯,加科思-B 公布,公司附属公司北京加科思新药研发有限公司就其于2024年8月30日艾力斯就KRAS G12C抑制剂Glecirasib 及SHP2变构抑制剂JAB-3312订立的对外许可协议,已收到约人民币1.73亿元的款项,包括首付款人民币1.5亿元及部分研发开支补偿及其他款项。该首付款及部分研发开支补偿及其他款项的到账,进一步充盈了集团的现金储备,也将为集团后续管线研发的推进提供助力。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1187870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","688578","01167","BK0239","BK1574"],"gpt_icon":0},{"id":"2470406190","title":"和誉医药与艾力斯合作研发的口服小分子抑制剂获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2470406190","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470406190?lang=zh_cn&edition=full","pubTime":"2024-09-25 12:06","pubTimestamp":1727237192,"startTime":"0","endTime":"0","summary":"新京报讯 9月25日,上海和誉生物医药科技有限公司(和誉医药)发布公告,其独立发现并与上海艾力斯医药科技股份有限公司(艾力斯)合作研发的新一代EGFR(表皮生长因子受体家族成员之一)口 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20240925/c661956551.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20240925/c661956551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","159938","688578"],"gpt_icon":0},{"id":"2469110576","title":"艾力斯(688578)9月23日主力资金净卖出1508.86万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2469110576","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469110576?lang=zh_cn&edition=full","pubTime":"2024-09-24 08:25","pubTimestamp":1727137553,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年9月23日收盘,艾力斯报收于40.33元,下跌1.59%,换手率0.79%,成交量3.57万手,成交额1.44亿元。近5日资金流向一览见下表:艾力斯融资融券信息显示,融资方面,当日融资买入738.09万元,融资偿还1630.18万元,融资净偿还892.1万元。艾力斯主营业务:专注于肿瘤治疗领域的创新药企业,目前已在非小细胞肺癌小分子靶向药领域构建了优势研发管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092400006184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"gpt_icon":0},{"id":"2469193241","title":"艾力斯(688578.SH):AST2303片获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2469193241","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469193241?lang=zh_cn&edition=full","pubTime":"2024-09-23 17:42","pubTimestamp":1727084563,"startTime":"0","endTime":"0","summary":"智通财经APP讯,艾力斯(688578.SH)公告,公司近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,同意AST2303片在携带EGFRC797S突变的晚期非小细胞肺癌成人患者中开展临床试验。公告显示,AST2303片(ABK3376片)是高选择、可入脑的新一代EGFR口服小分子抑制剂,可高效抑制EGFRC797S突变。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1185917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["03347","688578","BK1141","BK1583","BK0239","BK1576"],"gpt_icon":0},{"id":"2469193115","title":"艾力斯最新公告:AST2303片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2469193115","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469193115?lang=zh_cn&edition=full","pubTime":"2024-09-23 17:41","pubTimestamp":1727084476,"startTime":"0","endTime":"0","summary":"艾力斯公告,公司近日收到国家药监局核准签发的《药物临床试验批准通知书》,同意AST2303片在携带EGFR C797S突变的晚期非小细胞肺癌成人患者中开展临床试验。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092300022652.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578","03347","BK1576","BK1583","BK1141"],"gpt_icon":0},{"id":"2468445965","title":"艾力斯09月19日主力资金流出2208万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2468445965","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468445965?lang=zh_cn&edition=full","pubTime":"2024-09-19 15:19","pubTimestamp":1726730357,"startTime":"0","endTime":"0","summary":"09月19日, 艾力斯股价涨0.28%,报收42.35元,成交金额2.35亿元,换手率1.24%,振幅5.52%,量比1.73。艾力斯今日主力资金净流出2208万元,连续3日净流出,上一交易日主力净流出4565万元,今日环比减少51.63%。该股近5个交易日下跌5.89%,主力资金累计净流出1.21亿元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流出3.11亿元,其中净流出天数为16日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240919153300956ee8b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240919153300956ee8b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688578"],"gpt_icon":0},{"id":"2467031115","title":"艾力斯(688578)9月13日主力资金净卖出3154.75万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2467031115","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467031115?lang=zh_cn&edition=full","pubTime":"2024-09-14 08:22","pubTimestamp":1726273376,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年9月13日收盘,艾力斯报收于43.88元,下跌3.79%,换手率0.82%,成交量3.69万手,成交额1.64亿元。近5日资金流向一览见下表:艾力斯融资融券信息显示,融资方面,当日融资买入610.58万元,融资偿还859.68万元,融资净偿还249.1万元。艾力斯主营业务:专注于肿瘤治疗领域的创新药企业,目前已在非小细胞肺癌小分子靶向药领域构建了优势研发管线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091400006779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"gpt_icon":0},{"id":"2466938652","title":"艾力斯(688578)9月11日主力资金净卖出2592.46万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2466938652","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466938652?lang=zh_cn&edition=full","pubTime":"2024-09-12 08:15","pubTimestamp":1726100132,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年9月11日收盘,艾力斯报收于46.15元,上涨2.56%,换手率0.68%,成交量3.07万手,成交额1.41亿元。近5日资金流向一览见下表:艾力斯融资融券信息显示,融资方面,当日融资买入751.6万元,融资偿还1065.18万元,融资净偿还313.58万元。艾力斯主营业务:专注于肿瘤治疗领域的创新药企业,目前已在非小细胞肺癌小分子靶向药领域构建了优势研发管线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091200006335.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578"],"gpt_icon":0},{"id":"2466010095","title":"艾力斯09月10日遭主力抛售2021万元 环比增加236.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2466010095","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466010095?lang=zh_cn&edition=full","pubTime":"2024-09-10 15:18","pubTimestamp":1725952730,"startTime":"0","endTime":"0","summary":"09月10日, 艾力斯股价涨0.04%,报收45.00元,成交金额1.38亿元,换手率0.69%,振幅4.38%,量比1.08。艾力斯今日主力资金净流出2021万元,连续6日净流出,上一交易日主力净流出600万元,今日环比增加236.83%。该股近5个交易日下跌4.07%,主力资金累计净流出8152万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流出5848万元,其中净流出天数为13日。净流出前三个股分别为华东医药、华润双鹤、艾力斯。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409101531549559fc6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409101531549559fc6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688578"],"gpt_icon":0},{"id":"2465867347","title":"艾力斯(688578)9月6日主力资金净卖出3716.24万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2465867347","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465867347?lang=zh_cn&edition=full","pubTime":"2024-09-07 08:19","pubTimestamp":1725668382,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年9月6日收盘,艾力斯报收于44.86元,下跌4.76%,换手率0.87%,成交量3.93万手,成交额1.8亿元。近5日资金流向一览见下表:艾力斯融资融券信息显示,融资方面,当日融资买入1265.86万元,融资偿还2644.46万元,融资净偿还1378.6万元。艾力斯主营业务:专注于肿瘤治疗领域的创新药企业,目前已在非小细胞肺癌小分子靶向药领域构建了优势研发管线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090700005484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"gpt_icon":0},{"id":"2465601256","title":"艾力斯:\n您的意见已收悉,","url":"https://stock-news.laohu8.com/highlight/detail?id=2465601256","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465601256?lang=zh_cn&edition=full","pubTime":"2024-09-06 19:04","pubTimestamp":1725620652,"startTime":"0","endTime":"0","summary":"证券之星消息,艾力斯09月06日在投资者关系平台上答复投资者关心的问题。艾力斯董秘:尊敬的投资者您好,公司从上海和誉生物医药科技有限公司引进的口服小分子抑制剂AST2303已提交IND申请,该产品拟用于携带EGFRC797S突变的晚期非小细胞肺癌成人患者的治疗。艾力斯董秘:尊敬的投资者您好,截至2024年6月30日,公司普通股股东总数为13,429人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090600033656.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"gpt_icon":0},{"id":"2465511488","title":"XD艾力斯09月05日主力资金流出953万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2465511488","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465511488?lang=zh_cn&edition=full","pubTime":"2024-09-05 15:18","pubTimestamp":1725520689,"startTime":"0","endTime":"0","summary":"09月05日, XD艾力斯股价涨0.43%,报收47.10元,成交金额1.05亿元,换手率0.50%,振幅2.45%,量比0.59。XD艾力斯今日主力资金净流出953万元,连续3日净流出,上一交易日主力净流出1010万元,今日环比减少5.64%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为52.63%,平均跌幅为2.25%。该股近5个交易日下跌1.87%,主力资金累计净流出1013万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流入4157万元,其中净流入天数为10日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024090515250995e41c40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024090515250995e41c40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688578"],"gpt_icon":0},{"id":"2464341479","title":"艾力斯09月04日遭主力抛售1010万元 环比增加186.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2464341479","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464341479?lang=zh_cn&edition=full","pubTime":"2024-09-04 15:19","pubTimestamp":1725434352,"startTime":"0","endTime":"0","summary":"09月04日, 艾力斯股价跌0.02%,报收47.15元,成交金额1.09亿元,换手率0.51%,振幅3.03%,量比0.60。艾力斯今日主力资金净流出1010万元,上一交易日主力净流出352万元,今日环比增加186.93%。|09月04日主力加仓幅度前10个股||#|股票简称|主力净额占比|#|N富特科技|29.36%|#|日久光电|4.84%|#|科恒股份|4.18%|#|华瓷股份|4.15%|#|德尔股份|4.13%|#|C益诺思|4.07%|#|海科新源|3.40%|#|开开实业|3.30%|#|华升股份|2.90%|#|丰元股份|2.43%|艾力斯所在的化学制药行业,今日主力净流出1.91亿元,行业排名11/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409041536509edee890&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409041536509edee890&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688578"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-12-02","address":"上海市浦东新区周浦镇凌霄花路268号","stockEarnings":[{"period":"1week","weight":0.3682},{"period":"1month","weight":0.137},{"period":"3month","weight":-0.1346},{"period":"6month","weight":0.2125},{"period":"1year","weight":0.4301},{"period":"ytd","weight":0.3409}],"companyName":"上海艾力斯医药科技股份有限公司","boardCode":"AI0027","perCapita":"33509股","boardName":"医药制造业","registeredCapital":"45000万元","compareEarnings":[{"period":"1week","weight":0.2138},{"period":"1month","weight":0.1739},{"period":"3month","weight":0.1133},{"period":"6month","weight":0.0871},{"period":"1year","weight":0.0727},{"period":"ytd","weight":0.1215}],"survey":" 上海艾力斯医药科技股份有限公司是一家专注于肿瘤治疗领域的创新药企业,主要产品包括艾氟替尼(第三代EGFR-TKI)、阿利沙坦酯等。目前,已在非小细胞肺癌小分子靶向药领域构建了丰富的研发管线。公司自主研发成功并对外转让的已上市产品为阿利沙坦酯片,关于阿利沙坦酯《抗高血压化学1.1类创新药物——艾力沙坦的III期临床研究》课题获得国家“重大新药创制”科技重大专项,其临床研究入选国家高技术研究发展计划(863计划)。","serverTime":1727872205419,"listedPrice":22.73,"stockholders":"13429人(较上一季度增加22.81%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾力斯(688578)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾力斯(688578)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾力斯,688578,艾力斯股票,艾力斯股票老虎,艾力斯股票老虎国际,艾力斯行情,艾力斯股票行情,艾力斯股价,艾力斯股市,艾力斯股票价格,艾力斯股票交易,艾力斯股票购买,艾力斯股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾力斯(688578)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾力斯(688578)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}